Gene expression data of locally advanced rectal cancer patients by KRAS status

Stromal and extracellular matrix related genes are downregulated in KRAS mutant rectal adenocarcinoma We used Affymetrix U133 platform to profile the differences in the transcriptome of KRAS-wild-type and KRAS-mutant rectal cancer specimens RNA was extracted from 76 microsatellite stable pre-treatment biopsy samples from locally advanced rectal cancer patients accrued through the TIMING trial (ClinicalTrials.gov, number NCT00335816) and differential gene expression analysis was performed based on KRAS mutation status

KRAS突变型直肠腺癌肿瘤组织中，基质与细胞外基质（extracellular matrix）相关基因呈现表达下调趋势。本研究采用Affymetrix U133芯片平台，对KRAS野生型与KRAS突变型直肠癌标本的转录组（transcriptome）差异进行解析。研究样本取自通过TIMING试验（ClinicalTrials.gov，编号NCT00335816）招募的局部晚期直肠癌患者，共收集76份微卫星稳定（microsatellite stable）的治疗前活检样本并提取总RNA，随后基于KRAS突变状态完成差异基因表达分析。